Mercados españoles cerrados

LAVA Therapeutics N.V. (LVTX)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
2,6050+0,0850 (+3,37%)
A partir del 11:28AM EDT. Mercado abierto.

LAVA Therapeutics N.V.

Yalelaan 60
Utrecht 3584 CM
Netherlands
31 630 00 30 35
https://www.lavatherapeutics.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo55

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Stephen Allen Hurly M.B.A., M.Sc.CEO, Pres & Exec. DirectorN/AN/A1968
Mr. Peter RosVP of Fin.N/AN/A1972
Dr. Hans van der Vliet M.D., Ph.D.Chief Scientific OfficerN/AN/A1974
Ms. Amy Garabedian J.D.Gen. Counsel & Corp. Sec.N/AN/A1976
Mr. Wouter van HunnikVP & Head of HRN/AN/AN/A
Dr. Benjamin Winograd M.D., Ph.D.Chief Medical OfficerN/AN/A1957
Dr. Ton Adang Ph.D.Chief Devel. OfficerN/AN/A1961
Dr. Paul W. H. I. Parren Ph.D.Exec. VP, Head of R&D and MDN/AN/A1964
Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Gobierno corporativo

El ISS Governance QualityScore de LAVA Therapeutics N.V., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.